|
- Update on hemophilia gene therapy in Canada
In October 2023, Health Canada approved CSL Behring’s Hemgenix (etranacogene dezaparvovec) gene therapy for the treatment of hemophilia B It is indicated for the treatment of adults with hemophilia B who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- etranacogene dezaparvovec | CDA-AMC
HEMGENIX (etranacogene dezaparvovec) is indicated for treatment of adults (aged 18 years of age or older) with Hemophilia B (congenital Factor IX deficiency) who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- Medication Trend Updates and Formulary Changes 2nd Quarter 2023
Humira is FDA-approved to treat several autoimmune conditions in adult and children including rheumatoid arthritis, Crohn’s disease and ulcerative colitis The Humira biosimilars launching in 2023 are approved for most of the same indications as Humira, with two exceptions
- PHARMACY POLICY STATEMENT - CareSource
Hemgenix is a one-time single infusion and will not be reauthorized CareSource considers Hemgenix (etranacogene dezaparvovec) not medically necessary for the treatment of conditions that are not listed in this document
- HEMGENIX® (etranacogene dezaparvovec-drlb) | FAQs for Healthcare Providers
HEMGENIX is the first‑ever gene therapy for hemophilia B, and as you discuss it with your patients, important questions can arise Here, you can find answers to some of these common questions about treatment with HEMGENIX
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding Gene therapy for hemophilia B aims to establish sustained factor IX
- Medical policy announcements - Blue Cross Blue Shield of Massachusetts
New 2023 Category III CPT Codes All category III CPT Codes, including new 2023 codes, are non-covered unless they are explicitly described as “medically necessary” in a BCBSMA medical policy
- Q2 2023 Gene Therapy Report: Promising new treatments on the . . . - Caremark
Hemophilia A – Hemgenix, a gene therapy to treat severe hemophilia B, was approved in 2022 There may soon be one to treat severe hemophilia A as well Hemophilia A is much more prevalent – representing 80 percent of overall hemophilia cases
|
|
|